JP2023159309A5 - - Google Patents
Info
- Publication number
- JP2023159309A5 JP2023159309A5 JP2023134673A JP2023134673A JP2023159309A5 JP 2023159309 A5 JP2023159309 A5 JP 2023159309A5 JP 2023134673 A JP2023134673 A JP 2023134673A JP 2023134673 A JP2023134673 A JP 2023134673A JP 2023159309 A5 JP2023159309 A5 JP 2023159309A5
- Authority
- JP
- Japan
- Prior art keywords
- nemolizumab
- pharmaceutical composition
- mobile phase
- column
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026012833A JP2026063423A (ja) | 2021-12-22 | 2026-01-29 | 生物活性が低下した抗体バリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021207714 | 2021-12-22 | ||
| JP2021207714 | 2021-12-22 | ||
| JP2023501876A JP7721630B2 (ja) | 2021-12-22 | 2022-12-21 | 生物活性が低下した抗体バリアント |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501876A Division JP7721630B2 (ja) | 2021-12-22 | 2022-12-21 | 生物活性が低下した抗体バリアント |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026012833A Division JP2026063423A (ja) | 2021-12-22 | 2026-01-29 | 生物活性が低下した抗体バリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023159309A JP2023159309A (ja) | 2023-10-31 |
| JP2023159309A5 true JP2023159309A5 (cg-RX-API-DMAC7.html) | 2025-09-24 |
| JP7812826B2 JP7812826B2 (ja) | 2026-02-10 |
Family
ID=86902603
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501876A Active JP7721630B2 (ja) | 2021-12-22 | 2022-12-21 | 生物活性が低下した抗体バリアント |
| JP2023134673A Active JP7812826B2 (ja) | 2021-12-22 | 2023-08-22 | 生物活性が低下した抗体バリアント |
| JP2026012833A Pending JP2026063423A (ja) | 2021-12-22 | 2026-01-29 | 生物活性が低下した抗体バリアント |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501876A Active JP7721630B2 (ja) | 2021-12-22 | 2022-12-21 | 生物活性が低下した抗体バリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026012833A Pending JP2026063423A (ja) | 2021-12-22 | 2026-01-29 | 生物活性が低下した抗体バリアント |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250163163A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4455163A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7721630B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260007630A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613503A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340249A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023120561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3284480T3 (fi) | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2418220T (pt) * | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| ES2544888T3 (es) | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| TWI548418B (zh) | 2007-12-05 | 2016-09-11 | 中外製藥股份有限公司 | Anti-NR10 / IL-31RA antibody and its use |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| KR20260090008A (ko) * | 2017-11-01 | 2026-06-16 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 및 아이소폼 |
| SG11202009629YA (en) * | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
-
2022
- 2022-12-21 WO PCT/JP2022/047035 patent/WO2023120561A1/ja not_active Ceased
- 2022-12-21 KR KR1020257042067A patent/KR20260007630A/ko active Pending
- 2022-12-21 CN CN202280089597.4A patent/CN118613503A/zh active Pending
- 2022-12-21 EP EP22911263.6A patent/EP4455163A4/en active Pending
- 2022-12-21 TW TW111149176A patent/TW202340249A/zh unknown
- 2022-12-21 JP JP2023501876A patent/JP7721630B2/ja active Active
- 2022-12-21 US US18/721,311 patent/US20250163163A1/en active Pending
- 2022-12-21 KR KR1020237004346A patent/KR102902883B1/ko active Active
-
2023
- 2023-08-22 JP JP2023134673A patent/JP7812826B2/ja active Active
-
2026
- 2026-01-29 JP JP2026012833A patent/JP2026063423A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103288953B (zh) | 一种血浆中功能性蛋白质的分离纯化方法 | |
| RU2610667C2 (ru) | Способ очистки белков | |
| JP5948343B2 (ja) | トランスジェニックイネの子実からヒト血清アルブミンを精製する方法 | |
| JP6039550B2 (ja) | タンパク質の精製装置および方法 | |
| JP7430012B2 (ja) | アダリムマブのnon-protein a精製方法 | |
| CN111876393A (zh) | 一种大规模快速生产高纯度高活性慢病毒载体的方法 | |
| JP2023537565A5 (cg-RX-API-DMAC7.html) | ||
| CN105669560A (zh) | 一种从发酵液中分离提取四氢嘧啶的方法 | |
| CN103570820B (zh) | 一种重组人促卵泡激素的纯化方法 | |
| IL194629A (en) | Purification processes for isolation of pure vascular stomatitis from cell culture | |
| JP7512891B2 (ja) | ポリペプチドの分離方法、ポリペプチドの製造方法及びポリペプチドの精製装置 | |
| CN111304193A (zh) | 一种大规模快速纯化质粒dna的方法 | |
| CN102174100A (zh) | 多肽cw7213纯化工艺方法 | |
| TW201841933A (zh) | 使用陽離子交換層析法純化同功抗體之方法 | |
| CN115894663A (zh) | 一种重组人白细胞介素-2纯化方法 | |
| CN114645025A (zh) | 一种人源atp合成酶的纯化方法 | |
| CN119371491B (zh) | Pegcetacoplan的纯化方法和制备方法 | |
| TWI670278B (zh) | 高純度低內毒素碳水化合物(hple)組合物及其分離方法 | |
| TW201900257A (zh) | 使用親和力層析術純化抗體或其抗體片段的方法 | |
| JP2012214408A (ja) | 澄明液中に分散した不純物凝集体を除去することによるタンパク質の精製方法 | |
| CN102286069A (zh) | 一种有机溶剂沉淀分离初步提纯谷胱甘肽发酵液的方法 | |
| AU2019242986B2 (en) | Bordetella pertussis-derived protein-obtaining method including affinity chromatography process | |
| KR20250011797A (ko) | 알부민이 융합된 단백질의 정제방법 | |
| CN116874446A (zh) | 一种3-(n-吗啉基)-2-羟基丙磺酸钠合成工艺 | |
| CN119019522A (zh) | 一种纯化齐考诺肽的方法 |